Kornimate/medical-research-clean huggingface dataset:
local opera viewing combined medical gymnastics for elderly psci

Conditions: Post-stroke Cognitive Impairment

Summary: local opera viewing combined medical gymnastics for elderly psci

cognitive impairment and hemiplegia are the two major problems faced by elderly patients with cognitive impairment after stroke. the application of local drama viewing and combined medical gymnastics training aims to improve sports and cognitive function. local drama viewing and medical gymnastics training integrates drama art cognition and medical sports, is a beneficial scientific attempt. to construct a local opera viewing combined medical gymnastics training program for elderly patients with post-stroke cognitive impairment, and to explore its feasibility, acceptability and safety.

Eligibility criteria:
inclusion criteria: stroke patients who were hospitalized in the department of neurology of zhangzhou hospital and met the psci diagnostic criteria of the expert consensus on the prevention and treatment of cognitive impairment after stroke in china were the subjects of the study. ① stroke patients confirmed by neuroimaging, onset time within 1 week; (2) cognitive impairment occurs after stroke events; ③ the scores of the simple mental state examination scale were points in the illiterate group, points in the primary school group, points in the secondary school group, and points in the college group; ④ can maintain independent sitting position ≥30 min; ⑤ age ≥60 years old; ⑥ volunteer to join the study and receive intervention treatment. exclusion criteria: * other causes affect or lead to cognitive impairment, such as consciousness disorder, malignant tumor, severe liver and kidney insufficiency; ② there are serious cardiopulmonary and other systemic diseases; visual or hearing impairment; ④ have emotional behavior abnormalities and mental illness (including depression); ⑤ a history of alcohol or drug abuse
relationship between systemic fatty acid availability and insulin sensitivity

Conditions: Obesity

Summary: the investigators specific aim is to compare the relationship between systemic fatty acid availability and insulin sensitivity in a relatively homogenous population of obese adults. the investigators anticipate 1) greater systemic fatty acid availability will be associated with lower insulin sensitivity and 2) greater systemic fatty acid availability will be associated with greater accumulation of fatty acid intermediates and pro-inflammatory markers.


Eligibility criteria:
inclusion criteria: * body mass index \[bmi\]: 35-45 kg/m2; all women must be pre-menopausal; non-exerciser (no regularly planned exercise/physical activity) exclusion criteria: * weight instability ≥ ±5 lbs. in past month; medications known to affect lipid and/or glucose metabolism; pregnancy or actively breast feeding

Keywords: insulin sensitivity fatty acid metabolism
molecular biomarkers of response to radiation therapy in breast cancer

Conditions: Breast Cancer; Radiotherapy Side Effect

Summary: the purpose of this study is to identify potential genetic and other molecular biomarkers of response to radiation therapy in breast cancer that may help to personalize breast cancer radiation treatment in the future.

monocentric prospective clinical study including dcis patients treated at the institute of oncology ljubljana. patients treated with adjuvant radiotherapy and without systemic therapy are eligible for the study. adverse events of radiation treatment will be assessed after radiotherapy and during 5-year follow up and classified according to common terminology criteria for adverse events v5.0. molecular biomarkers will be assessed before radiotherapy, after radiotherapy and during follow up. dna will be isolated from whole blood samples obtained before radiation treatment. circulating biomarkers will be isolated from plasma samples before treatment, after treatment and during follow-up. written informed consent will be obtained from all included patients and the study design was approved by the national medical ethics committee.

Eligibility criteria:
inclusion criteria: * breast cancer patients with dcis with an indication for adjuvant radiation therapy exclusion criteria: * any specific systemic oncological therapy
study of the sensitivity of manual vs electric aspiration to detect completed early abortion

Conditions: Induced Abortion

Summary: with sensitive urine pregnancy tests, women are now able to confirm very early pregnancies. however, approximately one third of abortion facilities do not offer abortions at less than six weeks of pregnancy. providers may be concerned that they will be unable to identify products of conception (pocs) in uterine aspirates after early abortion and about the time, cost and risk associated with following serum hcg levels when completed abortion cannot be confirmed by gross inspection. many providers believe that manual vacuum aspiration (mva) causes less destruction of pregnancy tissue and therefore may increase the likelihood of identifying pocs on gross inspection. no published reports specifically compare mva to electric vacuum aspiration (eva) for the detection of complete products of conception and none compare mva and eva at less than 6 weeks of pregnancy. we, the investigators, propose to conduct a randomized controlled trial comparing the sensitivity of mva to eva for the detection of completed abortion in 500 women with pregnancies of less than 6 weeks gestation at a large inner city family planning center. we will measure positive identification of pocs on gross inspection in patients subsequently shown to have completed abortions. we hypothesize that the rate of true positive detection of pocs will be higher in dilation and curettage (d\&c) using mva than eva.


Eligibility criteria:
inclusion criteria: * gestational sac size \<12 mm or no visible sac (with positive pregnancy test) day of surgical abortion * no medical contraindications to outpatient abortion at study site exclusion criteria: * not able to consent * suspected ectopic pregnancy (pelvic mass, unilateral pain, or detection on ultrasound), suspected molar pregnancy, or no sac and vaginal bleeding suspicious for completed spontaneous abortion * failed medication abortion

Keywords: induced abortion termination of pregnancy manual vacuum aspiration electric vacuum aspiration
cytoreductive prostatectomy combined with triple or dual systemic therapy in mhspc patients

Conditions: Metastatic Prostate Cancer; Therapy, Directly Observed

Summary: to evaluate: the radiographic progression-free survival (rpfs) of metastatic hormone-sensitive prostate cancer (mhspc) patients treated with androgen deprivation therapy (adt) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (crp)

to investigate the multimodality approaches for mhspc

Eligibility criteria:
inclusion criteria: 1. male aged ≥18 and ≤75; 2. histologically confirmed prostate adenocarcinoma; 3. evidence of metastasis confirmed by magnetic resonance imaging (mri)/computed tomography (ct) scan, bone scan, or histology; 4. clinical stage m1a (distant lymph node positive), m1b (bone metastasis), or m1c (visceral organ metastasis); 5. prostate cancer has not received local treatment (e.g., prostate radiotherapy, cryotherapy, etc.); 6. the surgeon believes the prostate can be removed; exclusion criteria: 1. the surgeon believes the disease is unresectable; 2. life expectancy less than 2 years; 3. active spinal cord compression; 4. history of prior local treatment for prostate cancer; 5. difficulty swallowing, chronic diarrhea, intestinal obstruction, and other factors affecting drug intake and absorption; 6. refusal to sign the informed consent; 7. investigator believes the individual is not suitable for inclusion.

Keywords: prostate cancer cytoreductive prostatectomy
long-term, high blood flow hemoadsorption therapy in patients undergoing maintenance hemodialysis

Conditions: Chronic Kidney Diseases; Hemodialysis

Summary: objective：the purpose of the study is to confirm that extending the duration of hemoadsorption (ha) and increasing blood flow during the ha+hemodialysis (hd) treatment process is safe and feasible, and to verify that extending the hp treatment duration can further increase the clearance of protein-bound uremic toxins. methods: the study employs a multicenter, prospective, cohort design with a self-controlled before-and-after comparison. the duration of ha+hd treatment for maintenance hemodialysis (mhd) patients is extended to 4 hours, and the extracorporeal blood flow rate is increased to over 250-350 ml/min. the safety of the treatment is assessed by evaluating the safety of the procedure; the levels of relevant toxins in the patients' blood are measured before and after treatment, and the clearance rate of uremic toxins after a single treatment is calculated and compared with the self-controlled before-and-after data to determine whether the modified protocol can remove more uremic toxins.


Eligibility criteria:
inclusion criteria: maintenance hemodialysis patients with uremia receive regular ha+hd treatment exclusion criteria: plasma albumin \ 300×10\^9/l; hypercoagulable state allergy to the hemoperfusion device; new cardiovascular or cerebrovascular diseases; poor vascular access function, extracorporeal circulation blood flow unable to reach 250ml/min ultrafiltration volume \>4500ml in a single dialysis session use of non-heparin anticoagulants inability to comply with the procedures of this study other conditions deemed unsuitable for participation in this study by the investigator -

Keywords: protein-bound uremic toxins hemoadsorption
evaluate the safety and efficacy of car-t cells in the treatment of refractory myasthenia gravis

Conditions: Myasthenia Gravis

Summary: this is a single-arm, open-label, single-center, phase i study. the primary objective is to evaluate the safety of cd19 car-t therapy for patients with refractory myasthenia gravis, and to evaluate the pharmacokinetics of cd19 car-t in patients.


Eligibility criteria:
inclusion criteria: * 1. age ≥18 and gender unlimited； * 2. confirmed as refractory myasthenia gravis with achr antibody positive and accord one of the following three conditions 1. repeated electrical stimulation suggests neuromuscular conduction deficits； 2. tensilon test and neostigmine test positive; 3. the doctor judged that the symptoms of mg improved after treatment with oral cholinease inhibitors; * 3. consistent with the clinical classification of mgfa myasthenia gravis iia-ivb (including iia，iib，iiia， iiib， iva，ivb) * 4. the baseline mg-adl score ≥5 and the musculi oculi related score\< 50 ； * 5. baseline qmg score\>11; * 6. regular treatment with poor efficacy and/or lack of effective treatment means that there is still recurrence or exacerbation after treatment with conventional hormones, immunosuppressants (such as azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine a, cyclophosphamide, etc.) or rituximab； * 7. the estimated survival time is more than 12 weeks; * 8. women of childbearing age who have negative urine pregnancy test before medication administration and agree to take effective contraceptive measures during the trial period until the last follow-up. exclusion criteria: * 1. epilepsy history or other central nervous system disease; * 2. during the screening visit, the patient's thymectomy was less than 12 months or thymectomy was necessary during the study period or thymic radiation therapy ; * 3. electrocardiogram shows prolonged qt interval, severe heart diseases such as severe arrhythm ia in the past; * 4. pregnant (or lactating) women; * 5. patients with severe active infections; * 6. active infection of hepatitis b virus or hepatitis c virus; * 7. systemic steroids have used in the 4 weeks before participating in the treatment (except recently or currently using inhaled steroids); * 8. those who have used any gene therapy products before; * 9. the proiferation rate is less than 5 times response to cd3/cd28 co-stimulation signal; * 10. serum creatinine \> 2.5mg/dl or alt / ast \> 3 times uln or bilirubin \> 2.0 mg /dl; * 11. those who suffer from other uncontrolled diseases are not suitable to join the study; * 12. hiv infection; * 13. any situation that the researchers believe may increase the risk of patients or interfere with the test results.
high intensity interval training versus moderate continuous training in heart failure with preserved ejection fraction

Conditions: Heart Failure; Diastolic Heart Failure

Summary: the purpose of this study is to determine whether high intensity interval training (hiit) is superior to moderate continuous training in increasing cardiopulmonary capacity in heart failure with preserved ejection fraction patients.

high intensity interval training (hiit) has been proved to increase oxygen consumption, having superior cardiovascular effect when compared to moderate continuous training (mct) in post-infarction patients (wisloff et al.) aerobic training also had shown positive effect on oxygen consumption and diastolic function in subjects with hfpef when compared to usual care (edelmann et al). however, the comparison of hiit and mct on improving functional capacity and diastolic function in hfpef patients has not yet been study.

Eligibility criteria:
inclusion criteria: * patients with heart failure with preserved ejection fraction (hfpef) of any etiology that have functional class of the new york heart association (nyha) between i and iii, left ventricular ejection fraction \> 50% and who meet clinical and echocardiography criteria for hfpef according to the consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the european society of cardiology (paulus et al.). patients should be clinical stable for the last 3 months and under optimized pharmacologic treatment, being capable of walking without limitations. exclusion criteria: * patients with exercise-induced unstable ventricular arrhythmias, unstable angina, moderate to severe valvular heart disease, severe pulmonary disease, severe anemia, cognitive limitations to understand study protocol, use of pacemaker, autonomic neuropathy, cardiovascular event for less than 3 months, congenital heart disease, terminal illness with less than 1 year of life expectancy, peripheral arterial disease with intermittent claudication or osteoarticular conditions limiting exercise will be excluded.
optical coherence tomography angiography (oct-a) in children (≥ 6 <14 years of age)

Conditions: Retinopathy of Prematurity; Diabetic Retinopathy

Summary: comparison of octa to conventional imaging modalities for the diagnosis of eye diseases in children

optical coherence tomography angiography (octa) is a new non-invasive imaging technique that employs motion contrast imaging to high-resolution volumetric blood flow information. octa compares the decorrelation signal between sequential oct b-scans taken at precisely the same cross-section in order to construct a map of blood flow. at present, level 1 evidence of the technology's clinical applications doesn't exist. the investigators plan to compare octa as an imaging modality to conventional imaging modalities used in clinical routine.

Eligibility criteria:
inclusion criteria: * patients (children ≥ 6 \<14 years of age) from the childrens hospital, university hospital bern requiring routine internal medical check-up for the diagnosis of diabetes or children attending routine eye exams at the department of ophthalmology, who are willing to participate in the study, and whos parents are willing to sign informed consent on behalf of their child. * patients need to be at least 6 years of age (but younger than 14 years) 6 years of age or younger exclusion criteria: * patients (children) who are not willing or able to participate, or potential participant's parents who are not willing to sign informed consent on behalf of their child. * patients younger than 6 years of age or 14 years or older. * patients (children) with epilepsy
impact of follicular and blood g-csf during a natural cycle of ivf

Conditions: Infertility

Summary: recently, scientists look into g-csf (granulocyte - colony stimulatin factor). the use of this molecule is increasing in reproduction pathology. high level of follicular and blood g-csf on the day of oocyte retrieval could correlate with higher pregnancy and implantation rates.


Eligibility criteria:
inclusion criteria: * women between 18 and 43 years old * women natural in vitro fecondation exclusion criteria: * no exclusion criteria
the impact of active nurse participation on adenoma detection during routine colonoscopy

Conditions: Adenoma

Summary: hypothesis-- nurse observation in addition to the colonoscopist while withdrawing the colonoscope from the cecum leads to a greater adenoma detection rate. methods- patients presenting for screening colonoscopy are randomized to nurse observation or usual practice. risk factors for adenoma development and the adenoma detection rate in each group will be evaluated.


Eligibility criteria:
inclusion criteria: * performance of screening colonoscopy exclusion criteria: * history of inflammatory bowel disease, gastrointestinal bleeding

Keywords: colonoscopy adenoma detection rate
quality of life in colorectal (ex-)cancer patients, based on the belgian cancer registry.

Conditions: Colorectal Cancer; Quality of Life

Summary: this study is collecting data on quality of life, (care)needs and socio-economic factors in colorectal (ex-)cancer patients via a written questionnaire completed by the patient him/herself. the collected data will be linked with the patient- and tumour characteristics available in the database of the belgian cancer registry and with the facturation data supplying information about diagnostic techniques and performed treatments (available via the insurance companies). based on the selection criteria, 1220 patients were finally selected from the database of the belgian cancer registry. these patients received an invitation letter by regular mail, a detailed questionnaire and an informed consent. the questionnaire contains topics as sociodemographic, life style, comorbidity, satisfaction with the provided information, care needs, quality of life, anxiety and depression, financial situation etc. the patients were asked to complete the questionnaire and send it back, together with the signed informed consent, to the study-collaborators. after 2-4 weeks, a reminder was sent. at that time, a reply card was added. if a patient doesn't want to participate in this study, a reason can be mentioned on the reply card. the collected data are linked with the clinical data. the dataset will be coded before analyses will start.


Eligibility criteria:
inclusion criteria: * invasive colorectal cancer (icd-10: c18-c19-c20) * patient knows his/her diagnosis of cancer * incidence in 2008, 2009 or 2010 * the patient is at least 18 years at diagnosis * the patient is maximal 90 years when completing the questionnaire * the patient lives in flanders and speaks dutch * the patient is treated/followed by 1 of the 7 participating hospitals * the patient is able to complete the questionnaire him/herself (no cognitive problems) exclusion criteria: * more than 1 invasive tumour diagnosed

Keywords: colorectal cancer quality of life questionnaires
open label trial of deceased donor livers transplanted after dhope with exvivo liver perfusion

Conditions: Liver Transplant Surgery; Liver Transplantation

Summary: the purpose of this clinical study is to confirm the safety and effectiveness of dual hypothermic oxygenated perfusion (dhope) using the liver assist to preserve deceased donor livers for transplantation.


Eligibility criteria:
participant inclusion criteria: 1. participant is able to provide informed consent and hipaa authorization 2. age ≥18 years 3. participant is registered as an active first-time liver transplant candidate on the united network for organ sharing (unos) waiting list for primary liver transplantation - for participants with hepatocellular carcinoma (hcc) as indication for orthotopic liver transplantation, the tumor must be within milan criteria or down-staged to milan criteria at the time of transplant 4. participant is willing to comply with the study requirements and procedures participant exclusion criteria: 1. participant will undergo concurrent multi-organ transplantations (liver-kidney, liver-lung, etc.) 2. participant is listed for liver transplantation due to fulminant liver failure (unos status 1a) 3. participant is listed for a repeat liver transplantation (\>1 graft) 4. participant is pregnant 5. participant is on respiratory (ventilator dependent) and/or cardiocirculatory support (defined as mechanical circulatory support which requires at least one intravenous inotrope to maintain hemodynamics) 6. participant is enrolled in an interventional clinical trial with an investigational drug or device 7. presence of other medical, social, or psychological conditions that in the investigator's opinion, could limit the participant's ability to participate in the clinical trial
human leucocyte antigen g and chronic heart failure

Conditions: Chronic Heart Failure

Summary: the human leukocyte antigen g (hla-g) is a non-classical, major histocompatibility complex class i (mhc-i) protein that modulates the immune response, inhibiting it in most cases. physiologically expressed in the cells of some tissues, it increases in inflammatory reactions. inflammation appears to play an important role in the development of chronic heart failure. this study aims to evaluate the levels of soluble hla-g in patients with heart failure and to investigate the relationships between hla-g and other clinical-functional parameters of the disease. investigators hypothesize that the plasma levels of hla-g could correlate with the clinical status of heart failure and could provide indications on patient's prognosis.


Eligibility criteria:
inclusion criteria: * patients with recent diagnosis of chronic heart failure as defined by the guidelines of the european society of cardiology (esc) and with cardiac ejection fraction \<40. * clinical stability in the previous month prior to recruitment. * absence of coexisting autoimmune diseases. exclusion criteria: * subjects with over one year chronic heart failure diagnosis and in clinical stability for less than 1 month. * presence of autoimmune diseases.
a sudy to evaluate the efficacy and safety of tnm001 in high-risk infants

Conditions: Respiratory Syncytial Virus Infections

Summary: this study is a phase 3 randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and immunogenicity of tnm001 in high-risk infants when entering their rsv season. approximately 201 infants will be randomized in a ratio of 2:1 to receive tnm001 or placebo. all subjects will be followed for 270 days after dosing. this study will be conducted at approximately 20 sites in china.


Eligibility criteria:
inclusion criteria: * 1.high risk infants under 1 year of age who are entering their first rsv season at the time of screening. * 2.subject's legal representative(s) is(are) able to understand and comply with the requirements and procedures of the protocol,including scheduled visits and sample collection. * 3.subject is available to complete the follow-up period. exclusion criteria: * 1. any fever (\> 38.0°c) or acute illness within 7 days prior to randomization * 2. history of rsv infection * 3. being hospitalized at the time of randomization * 4. currently receiving or expected to receive immunosuppressive therapy during the study period. * 5. renal impairment or hepatic dysfunction * 6. nervous system disease or neuromuscular disease * 7. known immunodeficiency including hiv, mother with hiv infection unless the child's infection has been excluded. * 8. known allergy history of immunoglobulin products, receipt or expected to receive immunoglobulins or blood products during the study period. * 9.receipt of rsv vaccine or mab * 10.receiving blood products before randomization